EXTRANODAL NATURAL KILLER/T-CELL LYMPHOMA, NASAL TYPE
Clinical trials for EXTRANODAL NATURAL KILLER/T-CELL LYMPHOMA, NASAL TYPE explained in plain language.
Never miss a new study
Get alerted when new EXTRANODAL NATURAL KILLER/T-CELL LYMPHOMA, NASAL TYPE trials appear
Sign up with your email to follow new studies for EXTRANODAL NATURAL KILLER/T-CELL LYMPHOMA, NASAL TYPE, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Engineered donor cells take on lymphoma in early trial
Disease control Recruiting nowThis early-phase study tests a new approach for patients with certain lymphomas (Hodgkin, NK/T-cell, and others) that have returned or not responded to treatment. The therapy uses immune cells from healthy donors that are specially trained in the lab to attack cancer cells carryi…
Matched conditions: EXTRANODAL NATURAL KILLER/T-CELL LYMPHOMA, NASAL TYPE
Phase: PHASE1 • Sponsor: Baylor College of Medicine • Aim: Disease control
Last updated Jun 27, 2026 13:07 UTC
-
New hope for rare blood cancer: Two-Drug combo trial launches
Disease control Recruiting nowThis phase 3 trial tests whether adding either belinostat or pralatrexate to standard chemotherapy helps people with newly diagnosed peripheral T-cell lymphoma live longer without their cancer getting worse. About 504 participants will be randomly assigned to one of three treatme…
Matched conditions: EXTRANODAL NATURAL KILLER/T-CELL LYMPHOMA, NASAL TYPE
Phase: PHASE3 • Sponsor: Acrotech Biopharma Inc. • Aim: Disease control
Last updated Jun 27, 2026 07:55 UTC